ZOM.V - Zomedica Pharmaceuticals Corp.

TSXV - TSXV Delayed Price. Currency in CAD
0.2850
0.0000 (0.00%)
At close: 9:30AM EST
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.2850
Open0.2850
Bid0.1100 x 0
Ask0.4500 x 0
Day's Range0.2850 - 0.2850
52 Week Range0.2850 - 0.5600
Volume4,800
Avg. Volume0
Market Cap30.791M
Beta (5Y Monthly)0.06
PE Ratio (TTM)N/A
EPS (TTM)-0.0950
Earnings DateFeb 24, 2020 - Feb 28, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Zomedica Announces $2.5 Million Registered Direct Offering

      Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or “Company”), a veterinary diagnostic company, announced today that it has entered into a definitive agreement with institutional investors for the issuance and sale in a registered direct offering of 20,833,334 of its common shares at a purchase price of $0.12 per share, for gross proceeds of $2.5 million. In addition, in a concurrent private placement, Zomedica will issue to the investors warrants to purchase up to 20,833,334 common shares, which represent 100% of the number of common shares issued in the registered direct offering, with an exercise price $0.20 per share and a five-year exercise period commencing six (6) months of the issuance date. The common shares (but not the warrants issued in the concurrent private placement or the common shares underlying such warrants) are being offered and sold in the registered direct offering by Zomedica pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-228926), including a base prospectus, previously filed with and declared effective by the Securities and Exchange Commission (SEC) on January 30, 2019.

    • GlobeNewswire

      Zomedica Files U.S. Patent Application for Fecal Parasite Detection

      Zomedica Pharmaceuticals Corp. (NYSE American: ZOM)(“Zomedica” or “Company”), a veterinary diagnostic company, announced today that the Company has filed a U.S. patent application covering compositions and methods for five fecal parasite detection assays for detecting parasitic infections in cats and dogs designed for use with its ZM-020 pathogen detection device. In early 2019 Zomedica previously submitted a U.S. provisional patent application covering compositions and methods for detecting urinary tract infections (UTIs) designed for use with its ZM-020 pathogen detection platform to detect urinary tract infections in dogs and cats.

    • GlobeNewswire

      Zomedica to Voluntarily Delist its Common Shares from TSX Venture Exchange Effective February 10, 2020

      ANN ARBOR, Mich., Jan. 30, 2020 -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM) (“Zomedica” or the “Company”)  a veterinary diagnostic and pharmaceutical.

    • GlobeNewswire

      Zomedica to Focus on TRUFORMA™ Commercialization

      Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), announced today that it intends to focus on the final development and commercialization of TRUFORMA™, its inaugural point-of-care diagnostic biosensor platform, and the first five assays for the detection of adrenal and thyroid disorders in cats and dogs. Verification of TRUFORMA’s™ initial assays is expected to be completed by the end of the first quarter of 2020. Assuming successful completion of verification, the goal is to complete validation by the end of the second quarter of 2020.

    • GlobeNewswire

      Zomedica Successfully Completes Development and Manufacturing Milestones for its Cancer Liquid Biopsy Platform

      Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, today announced it has successfully completed the development and manufacturing milestones for its reference lab cancer liquid biopsy platform. Zomedica is developing assays for the detection of hemangiosarcoma, osteosarcoma, and lymphoma, for use with its liquid biopsy platform. Lymphoma, osteosarcoma and hemangiosarcoma are three of the top five most commonly diagnosed canine cancers.

    • GlobeNewswire

      Zomedica Announces Management Changes

      Zomedica Pharmaceuticals Corp. (“Zomedica”) (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, announced that Gerald Solensky, Jr. has resigned as Chief Executive Officer, Chairman and a Director of Zomedica, effective immediately. Mr. Solensky will continue as a consultant to the Zomedica’s operating subsidiary, Zomedica Phamaceuticals, Inc. Shameze Rampertab, Chief Financial Officer, will act as interim CEO until a replacement is found.

    • GlobeNewswire

      Zomedica Expands ZM-006 Pilot Efficacy Study

      Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, announced today that it has widen its pilot efficacy study of ZM-006, initiated in partnership with University of Georgia’s (UGA) veterinary teaching hospital, to include Quakertown Veterinary Clinic, an American Animal Hospital Association (AAHA) accredited, high-traffic referral clinic in Pennsylvania with 37 veterinarians, of which 24 specialize in small animal health.

    • GlobeNewswire

      Zomedica Announces Third Quarter 2019 Financial Results

      Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (ZOM.V) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today reported consolidated financial results for the third quarter ended September 30, 2019.

    • GlobeNewswire

      Zomedica Announces 2019 Annual Meeting Results

      ANN ARBOR, Mich., Nov. 05, 2019 -- Zomedica Pharmaceuticals Corp. (TSX-V:ZOM) (“Zomedica” or “Company”), a veterinary pharmaceutical and health care solutions company, is.

    • GlobeNewswire

      Zomedica Commences Final TRUFORMA™ Diagnostic Verification Study

      Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, announced today that it has commenced the final verification study of the first five assays designed for use with its point-of-care diagnostic biosensor platform, TRUFORMA™. The verification study is evaluating the utility of the first five thyroid and adrenal assays intended for use with the TRUFORMA™ platform. The initial three thyroid assays are: canine and feline total T4 (thyroxine), canine free T4, and canine and feline TSH (thyroid stimulating hormone).

    • CORRECTION FROM SOURCE: Zomedica Pushes TRUFORMA(TM) Closer To Commercialization, Targeting $2.7 Billion Companion Animal Diagnostics Market
      Newsfile

      CORRECTION FROM SOURCE: Zomedica Pushes TRUFORMA(TM) Closer To Commercialization, Targeting $2.7 Billion Companion Animal Diagnostics Market

      Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSXV: ZOM) - In the article headline published on October 1, 2019, the reference to Zomedica's TRUFORMA companion pet diagnostic device was incorrectly titled as TRUFORM. This error was made by a third-party responsible for syndication processes and should not reflect on Zomedica, its trademarks, or its pipeline properties. A copy of the entire release follows.Miami Beach, Florida--(Newsfile Corp. - October 3, 2019) - Zomedica Pharmaceuticals Corp. ...

    • Zomedica Pushes TRUFORMA (TM) Closer To Commercialization, Targeting $2.7 Billion Companion Animal Diagnostics Market
      Newsfile

      Zomedica Pushes TRUFORMA (TM) Closer To Commercialization, Targeting $2.7 Billion Companion Animal Diagnostics Market

      Miami Beach, Florida--(Newsfile Corp. - October 1, 2019) - Zomedica, Inc. (NYSE American: ZOM) (TSXV: ZOM) is getting closer to commercializing its first potentially industry-changing product, TRUFORMA™, a point of care diagnostic platform with initial assays used to diagnose thyroid and adrenal disorders in dogs and cats. The device, which is on pace to launch by the end of first quarter of 2020, is expecting to earn a large share of the ...

    • Do Insiders Own Shares In Zomedica Pharmaceuticals Corp. (CVE:ZOM)?
      Simply Wall St.

      Do Insiders Own Shares In Zomedica Pharmaceuticals Corp. (CVE:ZOM)?

      The big shareholder groups in Zomedica Pharmaceuticals Corp. (CVE:ZOM) have power over the company. Institutions will...

    • GlobeNewswire

      Zomedica names Dr. Stephanie Morley President

      Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, today announced that Dr. Stephanie Morley, Chief Operations Officer and VP of Product Development, has been promoted to the role of President of Zomedica. Dr. Morley, who joined the initial management team of Zomedica shortly after its founding, has over 15 years of experience as a life science executive and practicing veterinarian with a broad career in operations, business development and clinical veterinary practice.

    • PCG Research Announces Publication of Report Covering Zomedica Pharmaceuticals Corp.
      Newsfile

      PCG Research Announces Publication of Report Covering Zomedica Pharmaceuticals Corp.

      Developer of Diagnostic and Pharmaceutical Solutions for the Companion Animal Market with Commercialization Activities Approaching New York, New York--(Newsfile Corp. - September 11, 2019) - PCG Research, the equity research division of PCG Advisory, Inc., a leading investor relations and strategic advisory firm based in New York City and focused on small and micro-cap public companies, today announced it has initiated coverage on Zomedica Pharmaceuticals, Corp. (NYSE: ZOM) PCG Research, the equity research division of ...

    • ACCESSWIRE

      Zomedica to Present at the Fall Investor Summit on Monday, September 16 in New York City

      NEW YORK, NY / ACCESSWIRE / September 11, 2019 / Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM), a veterinary diagnostic and pharmaceutical company, today announced its Chief Financial ...

    • GlobeNewswire

      Zomedica to Present at RHK Capital 2019 Disruptive Growth Conference, Fall Investor Summit, and Sidoti & Company Fall 2019 Investor Conference

      ANN ARBOR, Mich., Sept. 03, 2019 -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and pharmaceutical company, today announced that.

    • GlobeNewswire

      Animal Health Veteran Johnny D. Powers Joins Zomedica Board of Directors

      Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (ZOM.V) (“Zomedica” or the “Company”), a veterinary diagnostic and pharmaceutical company, today announced that, subject to the approval of the TSX Venture Exchange, Johnny D. Powers has been appointed to Zomedica’s board of directors as an independent director. Additionally, Powers will also serve as a member of the audit, compensation, and corporate governance committees of the board of directors. Powers has more than 30 years of experience leading business strategy, operations, sales and marketing, and product development in the human and pet medical diagnostics markets.

    • GlobeNewswire

      Zomedica Announces Second Quarter 2019 Financial Results

      Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (ZOM.V) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today reported consolidated financial results for the second quarter ended June 30, 2019. “We have made significant progress in the first half of 2019 with our development of TRUFORMA™, Zomedica’s point-of-care biosensor platform, as well as our digital data platform and other product lines,” said Gerald Solensky Jr., Chairman and CEO of Zomedica. $5,000,000 of the purchase price was paid in May 2019 and $7,000,000 was paid in June 2019.  The preferred shares do not have voting rights except to the extent required by applicable law and are not convertible into the Company’s common shares.

    • GlobeNewswire

      Zomedica Announces TRUFORMA™ Assay Updates and R&D Expansion

      Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, today announced additional development progress on two assays for its TRUFORMA™ point-of-care biosensor platform. Development of what Zomedica believes is the first-ever point-of-care assay for canine endogenous adrenocorticotropic hormone (eACTH) and an assay for feline thyroid stimulating hormone (feline TSH) demonstrates the potential of TRUFORMA™.

    • GlobeNewswire

      Zomedica’s Dr. Bonnie Bragdon to Speak at AVMA Convention 2019 on Sunday, August 4

      ANN ARBOR, Mich., July 25, 2019 -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and pharmaceutical company, today announced Dr..

    • GlobeNewswire

      Zomedica Announces Initiation of a Digital Data Platform Enhancing its Diagnostic Pipeline

      Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, announced it has initiated the development of a digital customer data platform to enhance customer experience and its diagnostic pipeline. Development efforts are focused on providing veterinarians access to diagnostic test result data and insights into patterns of disease across animal populations.

    • GlobeNewswire

      Zomedica Announces Completion of Initial Development of a Lymphoma Assay for its Canine Cancer Liquid Biopsy Platform

      Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (ZOM.V), a veterinary diagnostic and pharmaceutical company, today announced that it has completed initial development work on a blood-borne lymphoma cancer assay intended for use with its canine cancer liquid biopsy platform. According to the American Veterinary Medical Association, one in four dogs will develop cancer during their lifetime. Lymphomas represent approximately 10-25% of all cancers diagnosed in dogs.

    • GlobeNewswire

      Zomedica to Present at Raymond James Life Sciences and MedTech Conference

      ANN ARBOR, Mich., June 12, 2019 -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and pharmaceutical company, today announced that it.

    • GlobeNewswire

      Zomedica Announces $7 Million Second Tranche Closing of Preferred Shares

      ANN ARBOR, Mich., June 10, 2019 -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical.